Naveen Pemmaraju, MD

Dr. Pemmaraju is Associate Professor in the Department of Leukemia at MD Anderson Cancer Center in Houston.

Articles by Naveen Pemmaraju, MD

Naveen Pemmaraju, MDThe HemOnc Pulse Live | July 1, 2024
Dr. Pemmaraju discusses three major unanswered questions for myeloproliferative neoplasm researchers.
Ruben Mesa, MDUncategorized | June 7, 2024
In the last segment of the roundtable series, the panel discusses the future of myelofibrosis treatment.
Ruben Mesa, MDUncategorized | July 2, 2024
The panel discusses the four JAK inhibitors approved by the FDA: ruxolitinib, fedratinib, pacritinib, and momelotinib.
Ruben Mesa, MDThe HemOnc Pulse Live | June 7, 2024
In the sixth segment of the roundtable series, the panel discusses momelotinib and pacritinib treatment in myelofibrosis.
Ruben Mesa, MDThe HemOnc Pulse Live | June 7, 2024
The panel discusses fedratinib for myelofibrosis and whether it's used in the frontline or second line setting.
Ruben Mesa, MDThe HemOnc Pulse Live | June 7, 2024
In the fourth segment of the roundtable series, the panel discusses frontline ruxolitinib treatment for myelofibrosis.
Ruben Mesa, MDThe HemOnc Pulse Live | June 7, 2024
This roundtable session addresses which patients go directly to transplant, when to observe patients, and more.
Naveen Pemmaraju, MDThe HemOnc Pulse Live | July 26, 2024
The panel considered whether it’s time for new response criteria in myelofibrosis such as anemia improvement.
Ruben Mesa, MDVideo Insights | June 7, 2024
In the first segment of the roundtable series, the panel discusses how myelofibrosis is diagnosed and assessed.
Ruben Mesa, MDVideo Insights | June 7, 2024
Dr. Naveen Pemmaraju discusses the history of prognostic scoring systems and how they factor into frontline therapy planning.
Helen T. Chifotides, PhDMyelofibrosis | January 21, 2022
Experts discuss emerging therapeutic targets, the impact of recently approved agents, and incorporating them into practice.